

Table of Contents

Résumé.....	10
List of Articles.....	13
List of Abbreviations.....	14
1. Introduction.....	17
1.1 Epidemiology of obesity and infection.....	17
1.2 Obesity and risk of infection.....	18
1.3 Obesity and risk of hospital mortality.....	18
1.4 Pathogenesis for the increased risk of infection in obese individuals.....	19
1.5 Need for antibiotic therapy.....	22
1.6 Choice of antibiotic.....	22
1.7 Delivery of antibiotic therapy.....	27
1.8 The era of multidrug resistance to antibiotics and use of PK/PD concepts to optimize treatment.....	31
1.9 Clinical situations where PK changes in antibiotics are observed.....	33
1.10 Improvement of PD target attainment.....	39
1.11 Theoretical antibiotic dosage adjustments.....	41
1.12 Clinical studies on β -lactams in obese patients.....	52
1.13 Need for optimal antibiotic therapy in the obese patient population.....	56
2. Objectives.....	57
3. Patients and methods.....	59
3.1 Patient selection criteria.....	59
3.2 Standard β -lactam dosage regimens.....	61
3.3 Data collection.....	62
3.4 Body size descriptors.....	62
3.5 Serum sampling.....	62
3.6 Measurement of β -lactam serum concentrations.....	62
3.7 Measurement of the renal function.....	63
3.8 PK analyses.....	63
3.9 Estimation of fCFZ and tCFZ serum concentrations at 240 minutes after the start of the CFZ infusion (T240).....	64
3.10 Serum concentrations obtained from hypothetical antibiotic dosage regimens in critically ill patients.....	65
3.11 Adequacy of β -lactams.....	65
3.12 Risk factors for inadequate β -lactam serum concentrations.....	66
3.13 Evaluation of β -lactam dose adjustment based on a correction formula for weight in infected, critically ill patients.....	67
3.14 Statistical analysis.....	67
3.15 Ethics.....	68

4. Results	69
4.1 Evaluation of total body weight and body mass index cut-offs for increased cefazolin dose for surgical prophylaxis.....	69
4.2 Broad-spectrum β -lactams in obese non-critically ill patients.....	79
4.3 Standard drug regimens of piperacillin-tazobactam are insufficient to treat « difficult to treat » pathogens in obese, non-critically ill patients.....	87
4.4 Case-control study of drug monitoring of β -lactams in obese critically ill patients.....	94
5. Discussion	103
5.1 Adequacy of SDR.....	103
5.2 Importance of renal function.....	103
5.3 Importance of body size descriptors.....	111
5.4 Does obesity affect the PK of all β -lactams in the same manner ?.....	112
5.5 Protein binding.....	113
5.6 Limitations.....	113
6. Conclusions	115
7. Perspectives	117
7.1 Obesity.....	117
7.2 Other special patient populations.....	119
8. References	121